Patents by Inventor STEPHEN MALCOLM THOM
STEPHEN MALCOLM THOM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220265595Abstract: The invention relates to compounds of formula (IW-1) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA, RB, RC and RD are as defined herein.Type: ApplicationFiled: April 30, 2020Publication date: August 25, 2022Inventors: Michael Liam COOKE, David COUSIN, Matthew Colin Thor FYFE, Barry John TEOBALD, Stephen Malcolm THOM, Thomas Michael WAUGH
-
Patent number: 10941115Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 10, 2019Date of Patent: March 9, 2021Assignee: Oxular Acquisitions LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Publication number: 20190330155Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: July 10, 2019Publication date: October 31, 2019Inventors: Thomas Matthew BAKER, Matthew Colin Thor Fyfe, Geraint JONES, Stephen Malcolm THOM
-
Patent number: 10442828Abstract: There are provided compounds of: wherein T, A, Q, Z, R4, R5a, R5b, n, r, Het1 and Rx have meanings given in the description, which compounds are useful in synthesizing compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: June 28, 2018Date of Patent: October 15, 2019Assignee: Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom
-
Patent number: 10435361Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 5, 2017Date of Patent: October 8, 2019Assignee: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Gareth William Harbottle, Vedran Hasimbegovic, Premji Meghani, Aaron Rigby, Colin Sambrook-Smith, Stephen Malcolm Thom
-
Patent number: 10392346Abstract: There are provided compounds of formula IIb, wherein: LG1 represents imidazolyl, chloro, or aryloxy; and Z1 represents a structural fragment of formula V: wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 13, 2018Date of Patent: August 27, 2019Assignee: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Patent number: 10125100Abstract: There are provided compounds of formulas III and VIIa: or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula V, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: May 24, 2017Date of Patent: November 13, 2018Assignees: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Publication number: 20180319748Abstract: There are provided compounds of formula IIb, wherein: LG1 represents imidazolyl, chloro, or aryloxy; and Z1 represents a structural fragment of formula V: wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: July 13, 2018Publication date: November 8, 2018Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Geraint JONES, Stephen Malcolm THOM
-
Publication number: 20180305383Abstract: There are provided compounds of: wherein T, A, Q, Z, R4, R5a, R5b, n, r, Het1 and Rx have meanings given in the description, which compounds are useful in synthesizing compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: June 28, 2018Publication date: October 25, 2018Inventors: Matthew Colin Thor FYFE, Stephen Malcolm THOM
-
Patent number: 10072034Abstract: There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: April 6, 2017Date of Patent: September 11, 2018Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom
-
Publication number: 20180044288Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: October 5, 2017Publication date: February 15, 2018Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Gareth William HARBOTTLE, Vedran HASIMBEGOVIC, Premji MEGHANI, Aaron RIGBY, Colin SAMBROOK-SMITH, Stephen Malcolm THOM
-
Patent number: 9890185Abstract: There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: December 19, 2014Date of Patent: February 13, 2018Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom, Thomas Matthew Baker, Gareth William Harbottle, Vedran Hasimbegovic, Aaron Rigby
-
Patent number: 9796742Abstract: There are provided compounds of formula I, wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 4, 2016Date of Patent: October 24, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Michael Knaggs, Premji Meghani, Stephen Malcolm Thom
-
Patent number: 9790209Abstract: There are provided compounds of formula I, wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 1, 2016Date of Patent: October 17, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Premji Meghani, Matthew Alexander Henry Stent, Stephen Malcolm Thom, Claire Anne Walshe
-
Patent number: 9790174Abstract: There are provided compounds of formula IIb, wherein LG1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: September 9, 2016Date of Patent: October 17, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventor: Stephen Malcolm Thom
-
Publication number: 20170291917Abstract: There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: April 6, 2017Publication date: October 12, 2017Inventors: Matthew Colin Thor FYFE, Stephen Malcolm THOM
-
Patent number: 9783556Abstract: There are provided compounds of formula I, (I): wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 28, 2013Date of Patent: October 10, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Premji Meghani, Stephen Malcolm Thom
-
Publication number: 20170253563Abstract: There are provided compounds of formulas III and VIIa: or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula V, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: May 24, 2017Publication date: September 7, 2017Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Geraint JONES, Stephen Malcolm THOM
-
Patent number: 9751837Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 1, 2015Date of Patent: September 5, 2017Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Patent number: 9732063Abstract: In compounds of formula I: R1 to R5, Ar and X1 to X3 have defined meanings. The compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: November 15, 2013Date of Patent: August 15, 2017Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Fritz-Frieder Frickel, Matthew Colin Thor Fyfe, Premji Meghani, Stephen Malcolm Thom